Pomerantz Law Firm Issues Alert Regarding Pacira Biosciences Class Action Lawsuit for Shareholders

Shareholder Alert: Pacira Biosciences Class Action Lawsuit

On January 21, 2025, Pomerantz LLP announced the filing of a class action lawsuit against Pacira Biosciences, Inc. (NASDAQ: PCRX), aimed at shareholders who have incurred losses on their investments. This legal action arises from allegations of securities fraud, suggesting possible misconduct by the company's officers or directors. Investors are strongly encouraged to reach out to Pomerantz LLP for guidance on joining the lawsuit.

Background of the Lawsuit

The leading factor prompting the lawsuit concerns a substantial drop in Pacira’s stock value following an unfavorable court ruling regarding its pain management product, Exparel. On August 9, 2024, a federal court invalidated Pacira’s patent for Exparel, indicating that the patent was obvious and not novel. Consequently, Pacira's stock plunged by an astounding $10.66, which equated to a 47.67% fall, closing at $11.70 per share.

This alarming price decrease has caught the attention of investors, triggering the investigation into the company's business practices. As per the allegations, the management of Pacira may have misled shareholders regarding the security of their investments, which paved the way for this significant legal action.

Details for Shareholders

Shareholders who acquired Pacira securities within the specified Class Period are invited to step forward and request to be appointed as Lead Plaintiff of the class. They have until March 14, 2025, to make this request. Interested parties are advised to contact Danielle Peyton at Pomerantz LLP via email at [email protected] or by phone at 646-581-9980, extension 7980. It is recommended that those who reach out include their mailing address, telephone number, and the number of shares they purchased to facilitate further communication regarding the proceedings.

The Role of Pomerantz LLP

Pomerantz LLP is recognized as a leading firm specializing in corporate, securities, and antitrust class actions. With over 85 years of pioneering efforts led by its founder, the late Abraham L. Pomerantz, the firm has built a strong reputation and track record in recovering sizable damages for victims of securities fraud, corporate malpractice, and breaches of fiduciary duty. Their commitment to ensuring justice for investors shapes their ongoing endeavors in the realm of securities law.

Investors can get further information about this class action lawsuit on the Pomerantz website, where documents related to the case are also accessible. With this movement, Pomerantz seeks to uphold the rights of investors in the face of corporate wrongdoings, ensuring accountability within the financial sector.

For those contemplating their options in light of this situation, taking prompt action can be crucial in safeguarding their interests. As the legal proceedings unfold, aligning with expert legal representation can make a significant difference in how the outcome affects their portfolios.

Conclusion

The class action lawsuit against Pacira Biosciences, Inc. highlights critical issues surrounding investor protection. Any shareholder affected by the stock's decline should consider becoming involved in this action to uphold their rights. As deadlines approach, timely engagement will be vital for those seeking restitution for their losses.

Stay informed about updates regarding the lawsuit and act decisively to ensure your position is represented appropriately.